Cancer Update:

New Theories and Advances in Cancer Treatment

Townsend Letter
The Examiner of Alternative Medicine

By Prof. Serge Jurasunas, MD(Hom), ND

Complete References

1. Belpomme D. *Guérir du cancer ous!* en proteger (Cure or Protect Yourself from Cancer). Edition Fayard. Paris, France; 2005:166-167.
2. Warburg O. On the origin of cancer cells. *Science*. 1956;123 (3191): 309-314.
3. Bharat B, et al. Curcumin suppresses the paclitaxel-induced Nuclear Factor K-B in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Cancer Therapy*. October 2005.
4. Aggarwal ML, et al. The p53 network. *J Biolo Chem*. 1998; 273:1-4.
5. Vogt SR, Haupt Y. The cellular response to p53. The decision between life and death. *Oncogene*. 1999;18: 6145-6157.
6. Miyashita T, et al. Tumor suppressor p53 is a regulator of BcL2 and Bax gene expression in vitro and in vivo. *Oncogene*. 1994;9:1799-805.
7. Hockenberry DM, et al. BcL2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* (London). 1990;348:334-336.
8. Krajewski C, et al. Reduced expression of pro-apoptotic Bax is associated with a poor response rate to combination chemotherapy and shorter survival in women metastatic breast adenocarcinoma. *Cancer Res*. 1995;55:4471-4478.
9. Naseri MH, et al. Up-regulation of Bax and up-regulation of BcL2 during 3-nc mediated apoptosis in human cancer cells. *Cancer Cell Int*. 28 May 2015.
10. Scopa CD, et al. BcL2/Bax ratio as a predictive marker for therapeutic response to radiotherapy in a patient with colorectal cancer. *Appl Immunocytochemistry Molecular Morphology*. Dec 2001; 9(4): 328-334.
11. Kum Kum Jha, et al. Survivin expression and targeting in breast cancer. *Surg Oncol*. June 2012.
12. Shakrokl F, et al. Survivin expression is associate with features of biologically aggressive prostate carcinoma. *Cancer*. February 15, 2004;100(4).
13. Mirza A, et al. Human survivin is negatively regulated by wild type p53 and participates in p53 dependent apoptotic pathways. *Oncogene*. 2002;21:2631-22.
14. Rivlin N, Brosh R, Rotter V. Mutation in the p53 Tumor suppressor gene. *Genes Cancer*. April 2, 2011; 4: 466-474.
15. Oren M, Rotter V. Mutant p53 Gain-of-function in cancer. *Cold Spring Harb Perspect Biol*. February 2010;2 a001107.

16. Wikstroom P, et al. Transforming Growth Factor beta is associated with angiogenesis in metastasis and poor clinical outcome in prostate cancer. *The Prostate*. September 15, 1996.
17. Chechi A, Waning DL, Mohammed KS. The role of TGFB in breast cancer bone metastasis. *Advances in Bioscience and Biotechnology*. Published online October 13, 2013.
18. Aas T, et al. Specific mutations are associated with de novo resistance to doxorubicin in breast cancer patients. *Nature Medicine*. 1996; 2811-2814.
19. Oliver, et al. Tp53 mutations are associated with shorter survival in breast cancer independently of stage, grade, and hormone receptors status. *Clin Cancer Res*. 2006.
20. Warburg O. On respiratory impairment in cancer cells. *Science*. 1956; 124 (3215): 269-70.
21. Warburg O. Uber den Stoffwechsel der carcinomzell. *Die Naturwissenschaften* 1924; 12: 1131-1139.
22. Warburg O. The Prime Cause and Prevention of Cancer. Lecture at the meeting of the Nobel-Laureates on June 30.1966 Germany. Published by Konrad Triltsch, Wurzburg, Germany 1969. English edition by Dean Burk. National Cancer Institute. USA.
23. Warburg O, Versuche an Ubeeeerlebendem carcinom-Gewebe (Methodend) *Biochem Zeitschr*. 1923;142: 317-333.
24. Demetrius LA, Coy JF, Tuszynski JA. Cancer proliferation and therapy. The Warburg effect and quantum metabolism. *Theoretical Biology Medical Modeling*. 2010;7.2.
25. Gorbatchev A, Ouchida A, Queiroz AL. The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. *Molecular and Cellular Biology*. October 17, 2017; 37(24).
26. Navale AM, Paranjape AN. Glucose transporters. Physiological and pathological roles. *Biophys Rev*. March 2016; 8 (1): 5-9.
27. Eriksson M, et al. Effect of mutant p53 proteins in glycolysis and mitochondrial metabolism. *Mol Cell Biol*. 2017 Nov 28;37(24):e00328-17.
28. Szalbewski L. Expression of glucose transporters in cancer. Biochim Biophys-Acta. 2013; 1835:164-169.
29. Krzeslk A, et al. Expression of GLUT4 and GLUT3 glucose transporters in endometrial and breast cancers, *Pathol Oncol Res*. 2012; 18: 721-728.
30. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J Cell Physiol*. 2005; 202:654-662.
31. Medina RA, Owen GI. Glucose transporters. Expression, regulation, and cancer. *Biol Res*. 2002;33:9-26.
32. Alaya FR et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. *Molecules*. April 2010;15 (4): 2374-87.
33. Kuand R, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. *JCI Insight*. 2017; 2 e88815.

34. Scwartzwnberg-Bar-Yoseph F, Armoni M, Karmeli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. *Cancer Res*. 2004; 64 (7): 2627-33.
35. Cen Zhang, Juan Liu, Zhaohui Feng. Tumor associate mutant p53 drives the Warburg effect. *Nature Communication 4*. 2013; Article number 2935.
36. Bensaad K, et al. Tigar, a p53-inducible regulator of glycolysis and apoptosis. *Cell*. 2006; 126 (1): 107-20.
37. Hiroshi K, et al. Glycolytic enzymes can modulate cellular life span. *Cancer Res*. 2005; 65 (1):177-85.
38. Matoba S, et al. p53 regulates mitochondrial respiration. *Science*. 2006;312 (5780): 1650-3.
39. Ma W, et al. A pivotal role for p53. Balancing aerobic respiration and glycolysis. *J Bioenergy Biomenhr*. 2007;39 (3):243-6.
40. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. *European Journal of Cancer*. April 1997;33(5): 789-791.
41. Aubert G, Landsorp PM. Telomeres and Aging. *Physiological reviews*. 2008;88:557-579.
42. Kim NW, et al. Specific association of human telomerase with immortal cells and cancer. *Science*. 1994; 266: 2011-5.
43. Soria JC, et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. *Clin Cancer Res*. 1999; 917-5.
44. Sapi E, Okpokwasili NI, Rutherford T. Detection of telomerase positive circulating epithelial cells in ovarian cancer patients. *Cancer Detect Prev*. 2002; 26: 158-67.
45. Goldkorn A, et al. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG0421. A phase III metastatic castration-resistant prostate cancer trial. *Intl Journal of Cancer*. 2015:136:1856-62.
46. Mohammed A, et al. Roles of telomerase in cancer and advances in telomerase targeted therapies. *Genome Med*. 2016; 869.
47. Lieberman P. Brothers-in-Arms: How p53 and telomeres work together to stave off cancer. *Science Daily* (the Wistar Institute). January 15, 2016.
48. Akeshuma R, et al. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. *BJC*. 2001; 84 (11):1551-1555.
49. Hoas A, et al. Telomerase activity correlates with tumor aggressiveness and reflex therapy effect in breast cancer. *Int. Journal Cancer*. 1998;74:8-12.
50. Brittney-Shea H, Wright WE, Show JW. Telomerase and Breast Cancer. *Breast Cancer Research*. 2001;3:146-149.
51. Dobja-Kubica K, et al. Telomerase activity in non-small-cell-lung cancer. *Polish Journal of Thoracic and Cardiovascular Surgery*. 2016;13 (1): 15-20.
52. Hermann PC, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell*. 2007;1:313-23.
53. Colak S, Medema JP. Cancer stem cells- important players in tumor therapy resistance. *FEBS Journal*. 2014;281(21):4779-47791.
54. Ponte PM, Caicedo A. Stemness in cancer. Stem Cells, Cancer Stem Cells, and their Microenvironment. *Stem Cells International*. 2017: Article ID5619472.
55. Del Bufalo D, et al. Involvement of hTERT in apoptosis induced by interference with BcL2 expression in function. *Cell Death Differ*. 2005;12(14):29-38.
56. Bernuidez Y, et al. Telomerase confers resistance to caspase-mediated apoptosis. *Clin Intervent Aging*. 2006;1/15567.

57. Jurasunas S, Taylor OG. How to Target Mutant p53 in a case of Multiple Cancer Recurrence. *Townsend Letter*. August/Sept.2010; 68-71.
58. Cosan DT, Soyocak A. Inhibiting telomerase activity and inducing apoptosis in cancer cells by several natural food compounds. In: Bibo L, editor. *Review on Selected Topics of Telomere Biology*. Rijeka, Croatia; InTech: 2010;123-148.
59. Keating E, Martel F. Antimetabolic effects of polyphenols in breast cancer cells. Focus on glucose uptake and metabolism. *Frontiers in Nutrition*. April 16, 2018.
60. Vallianou NG, et al. Potential anticancer Properties and Mechanisms of action of curcumin. *Anticancer Research*. February 2015; 35(2): 645-65.
61. Halysz H, Lipinska N, Rubis B. Curcumin inhibits telomerase activity through human telomerase reverse transcriptase (TERT) in the MCF-7 breast cancer cell line. *Cancer Letter*. 2012;184(1):1-6.
62. Chakrabaity S, et al. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-526 cells. *Molecular Mechanisms of Mutagenesis.* 2006;596:81-90.
63. Jagodeesh S, et al. Genistein represses Telomerase activity via both transcriptional and posttranscriptional Mechanism in the human cancer prostate. *Cell Tumor and Stem Cell Biology*. February 2006.
64. Yanyan Li, et al. Targeting cancer stem cells by curcumin and clinical applications. *Cancer Letter*. January 2014;346 (2).
65. Huang W, Wan C, Luo Q. Genistein inhibits cancer stem cell-like properties and reduced chemoresistance of gastric cancer. *Intl Journal Mol Sci*. March 15, 2014;15(3):3432-3443.
66. Jurasunas S. NK cell-based immunotherapy in the treatment of cancer using a new Arabinoxylan compound. *Townsend Letter*. August/September 2019: 33-41.
67. Badr NK, et al. Arabinoxylan Rice Bran (MGn-3/Biobran enhances radiotherapy in animals bearing Ehrlich ascites carcinoma. *Journal of Radiation Research*. 2019; 1-12.
68. Lanzilli G, et al. Resveratrol down-regulates the growth of telomerase activity of breast cancer cells in vitro. *Int Journal Oncol*. March 2006;28:641-8.
69. Sadova D, Whitlock E, Kane SE. The green tea polyphenol epigallocatechin-3-gallate inhibits telomerase and induce apoptosis in drug-resistant lung cancer. *Biochemical and Biophysical Communication*. 2007;360:233-237.
70. Sun L, Wang X. Effects of Allicin on both telomerase activity and apoptosis in gastric cancer SGC 7901 cells. *World J Gastroenterol*. 2003;9(9):1930-4.
71. Moon D, et al. Sulphoraphane decrease viability and telomerase activity in hepatocellular carcinoma. Hep 3B cells through the reactive oxygen species-dependent pathways. *Cancer Letter*. September 2010; 295(2):60-66.
72. Yurtcu E, et al. Effects of silymarin and silymarin-doxorubicine applications on telomerase activity of human hepatocellular carcinoma cell line Hep G2. *J Buon*. May 2015;20(2): 555-561 (Journal of BUON in the official journal of the Balkan Univ of Oncology).
73. Oh NI, et al. Blocking Telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. *Cancer Res*. 2003;63:824-830.
74. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. *Cancer Metastasis Rev*. 2010; 29:465-482